The present invention provides a Fc.gamma.RIIa transgenic non-human animal
model for autoimmune disease, particularly arthritis. This invention also
provides a method of using this model to screen compounds that can reduce
aberrant immune activity including aberrant immune complex formation
aberrant immune complex clearance and immune complex induced
inflammation. This invention also provides means of using this model to
treat or prevent autoimmune disease.
